Perimenopause or Thyroid? How to Tell What's Actually Causing Your Symptoms

Is this perimenopause, my thyroid, or both?

If you’re in your forties and you’ve started feeling like a slightly different person — tired in a way sleep doesn’t fix, foggy, heavier around the middle, sleeping badly, finding more hair in the shower — you’ve probably already asked some version of this question. And you may have been given a quick answer: it’s your age. Or: your thyroid is normal.

Here’s the more honest answer. It is genuinely hard to know sometimes — and the question may be slightly the wrong shape, because it assumes these are two separate things competing to explain you.

They aren’t. These are all hormones, and they’re interconnected. Your thyroid has a very large impact on your hormone cascade — your estrogen, your progesterone, all of your sex hormones.

Which leads to something we see often enough that it shapes how we work. When the thyroid is off, it can pull a lot of hormones down with it — and on paper, that woman can look further into perimenopause than she actually is. Correct the thyroid, give it time, and re-run the hormone panel once the numbers look better and she’s feeling better, and the picture can look different. Sometimes considerably so.

It depends how far into the transition she really is. But either way, the principle holds:

Don’t skip over the thyroid and go directly to hormones. Look at both — because both matter, and they’re very interconnected.

Why these two are so hard to tell apart

Two things collide.

The symptoms genuinely overlap. Fatigue, weight change, brain fog, mood changes, poor sleep, hair thinning, dry skin, joint aches, low libido, cycle changes, feeling too hot or too cold — every one of those can belong to either picture.

And they arrive in the same stretch of life. Perimenopause typically begins in the forties. Hashimoto’s, the most common cause of hypothyroidism, commonly presents in adulthood and is frequently seen in midlife women — it doesn’t wait for the transition to finish.

The European Menopause and Andropause Society said it directly in its 2024 position statement: menopause and thyroid dysfunction share symptoms including menstrual irregularities, mood disorders, increased sweating, sleep disturbance and hair loss — and clinicians need greater awareness of that overlap so co-existing thyroid disease gets found rather than missed.

One more wrinkle: the classic signs of an overactive thyroid tend to become less obvious with age. The textbook presentation gets quieter exactly when the differential gets more crowded.

This article focuses on perimenopause — the years when cycles are still happening and hormones are fluctuating rather than settling. For the broader relationship between menopause, postmenopause and thyroid function, see Menopause and the thyroid.

The same symptom, two different textures

A list of shared symptoms won’t separate these. What sometimes helps is noticing how a symptom behaves — how it started, whether it’s constant, whether it moves with your cycle.

Fatigue. Thyroid fatigue tends to feel slower and heavier and fairly constant — like being turned down. Perimenopausal fatigue more often follows the night before: broken sleep, night sweats, and the flattening that comes after them.

How it began. One of the more useful questions is simply what did the onset look like? “I was doing great, and then all of a sudden I just don’t feel awesome” — with sleep problems, night sweats, vaginal dryness and low libido showing up together — points more toward the transition. A slow slide building over a long stretch points more toward thyroid.

Temperature. Hot flashes and night sweats are perimenopause’s signature. Being persistently cold when nobody else is leans thyroid.

Bowels and skin. Constipation and dry skin lean thyroid — and both get written off as incidental.

These shift the odds. They do not diagnose. Any one can appear in either condition, or in neither.

What makes us look harder at the thyroid

• Family history of autoimmune thyroid disease — Hashimoto’s, hypothyroidism, or other significant thyroid disease in close relatives. That makes us pay closer attention.
• Eyebrow thinning, constipation, thinning hair, dry skin, low energy, depression or anxiety in the history. These are nonspecific on their own; it’s the cluster that’s informative.
• Cycles that have grown longer and heavier (more on this below).

A note on family history of thyroid cancer. That’s a different signal, and worth keeping separate. It’s a structural and risk-history consideration that may make us more attentive to thyroid examination, nodules, ultrasound history and appropriate follow-up. It is not evidence that someone is hypothyroid, and it shouldn’t be read that way.

What pushes us more toward perimenopause

• Cycles that have become shorter and more rapid — and then started skipping. That sequence is more characteristic of the transition.
• A relatively abrupt change in how you feel, with sleep problems, night sweats, vaginal dryness and low libido clustering together.
• Hot flashes, which sit much more firmly on this side.

But there’s real overlap in all of it. Which is the point.

What your cycle can and can’t tell you

Cycle history is one of the more informative things you can bring to an appointment, and it’s often the thing nobody asks about in any detail.

Thyroid dysfunction really does change cycles. In one study of 171 patients with hypothyroidism, 23.4% had irregular menstrual cycles.

On heavier bleeding. There’s a real association here, and it’s worth being precise about it. Overt hypothyroidism has been associated with changes in hemostasis — including reduced von Willebrand factor and factor VIII activity, and a prolonged aPTT — which can contribute to a greater bleeding tendency in some patients. Acquired von Willebrand syndrome has been reported in roughly 2–5% of people with hypothyroidism, and there are cases in which correcting the hypothyroidism normalized the coagulation picture and resolved the heavy bleeding. So this is a genuine mechanism in a minority of patients — not the explanation for every heavy period, and not a diagnostic rule.

Practically: heavier, longer cycles are a clue worth following. And the direction of a change carries more information than the fact of it — longer and heavier leans thyroid, shorter-then-skipping leans transition.

When the thyroid is corrected, a cycle that had stretched out can come back toward twenty-eight days with lighter bleeding. That isn’t guaranteed — and heavy bleeding deserves evaluation in its own right regardless.

A representative example

The following is a composite — a pattern assembled to illustrate a point. It is not a specific patient, and it describes one possible course rather than a typical or expected outcome.

A woman in her mid-forties comes in tired, foggy and frustrated. Her periods have grown longer and noticeably heavier over about two years. Her hair is thinning, she’s cold when the house isn’t, and she’s constipated. She’s been told her thyroid is fine — a TSH was run, and it was in range.

A fuller evaluation shows thyroid antibodies present and a Free T3 near the bottom of the range, with a TSH technically within the lab range but not where we’d want it. A hormone panel run at the same time looks low across the board — and read on its own, that panel would suggest she is well into perimenopause.

We address the thyroid. Some months later she’s warmer, the bleeding has settled, and her cycle has shortened. We re-run the hormone panel and it reads better than the first one did. She may well still be entering perimenopause — treating her thyroid didn’t stop the transition and wouldn’t be expected to. What changed is that we can now see which part was thyroid and which part is the transition.

That’s the point: not that thyroid treatment fixes perimenopause, but that a single early snapshot can mislead, and reassessing after you’ve addressed something treatable is often what makes the picture legible. It doesn’t always play out this way.

When it’s both — and what we address first

Both is common, and the two aren’t independent — so the order matters.

In early perimenopause, we’re generally more concerned with addressing the thyroid first, and then seeing where the hormones land. If a woman is already postmenopausal, the sequencing changes — you may work on both at once, estrogen and progesterone alongside thyroid support. It depends on the case.

What we don’t do is treat one thing, declare the question answered, and stop looking.

What thyroid testing should actually look at

This is where our approach differs most visibly from a standard work-up, so we’ll be clear about which is which.

What a standard evaluation usually involves: TSH first, with Free T4 and thyroid antibodies added when indicated. Thyroid ultrasound is conventionally reserved for a palpable nodule, a goiter, or a specific structural question rather than used routinely.

Our clinical approach — the GFW expanded panel

For this particular question, a TSH alone — or a TSH plus a Free T4 — is not enough for the way we practice. We want antibodies, and we want imaging.

At minimum: thyroid ultrasound, TSH, Total T4, Free T3, and thyroid antibodies.

What we prefer to have in front of us: TSH, Total T4, Free T4, Free T3, Total T3, FTI, T3 uptake, reverse T3, TPO antibodies, thyroglobulin antibodies, and a thyroid ultrasound.

Where this list differs from routine guidance, and why. Mainstream thyroid guidance considers reverse T3 to be of limited value in routine hypothyroidism assessment, and FTI and T3 uptake are older measures that have largely been superseded by direct free-hormone assays. We include them selectively, as part of building a broader clinical picture — not as standard-of-care testing. Both things are true at once, and you should know which is which.

The reason for the wider net: you want to see the lay of the land before you start making decisions. Autoimmune thyroid disease can be underway before TSH ever moves, which is why antibodies aren’t optional for us.

It’s entirely reasonable to ask any clinician why a given test is — or isn’t — being ordered.

For what each marker contributes, see 9 thyroid tests you need and Normal TSH but still symptomatic?

Where we draw the line on TSH — and where guidelines draw it

TSH has real limits, but it isn’t useless.

Our clinical approach: a TSH above about 4 makes us strongly suspicious that there’s a meaningful thyroid problem, and it substantially lowers our threshold for considering thyroid hormone replacement in a symptomatic patient. It doesn’t make the decision by itself. We still evaluate the whole case — the rest of the thyroid panel, antibodies, ultrasound, symptoms, history, any previous response to thyroid medication, recent iodine exposure, pregnancy or fertility considerations, age, and whatever else is relevant to that person.

From a functional and optimization standpoint we also generally prefer not to see a TSH above about 2. But we don’t make treatment decisions from TSH alone, in either direction.

One caveat we apply specifically: recent iodine intake can cause a temporary rise in TSH that later declines. We don’t assume — we take a history and talk it through.

What guidelines say: a joint statement from the American Association of Clinical Endocrinologists, the American Thyroid Association and the Endocrine Society advises against routine or reflex treatment of a TSH between 4.5 and 10 — the operative word being routine. It also recommends confirming an elevated TSH on a repeat test, typically one to three months later, because some values come down on their own. Reference ranges widen with age, too; the upper limit of normal sits around 4.0 at age fifty and rises after that.

Where the debate actually sits. The question of what “normal” should mean isn’t a fringe argument. The National Academy of Clinical Biochemistry has suggested a narrower range of roughly 0.4–2.5 mIU/L, against the 0.3–5.0 many labs still print. That’s close to the range we work toward — so this is a live disagreement inside mainstream laboratory medicine, not simply functional medicine versus everyone else.

Where we land: the wide ranges take in a lot of people who don’t feel well. When we use functional ranges we’re looking for optimal function — what healthy thyroid function actually looks like — rather than waiting for overt disease to declare itself. We’re not waiting till things get so bad.

That’s a real difference in clinical philosophy, and you should know it exists so you can have the conversation with your own clinician.

Which thyroid medication

Our clinical approach: there isn’t one medication that fits everyone. We ask what you’ve tried before, what worked and what didn’t, because previous response is genuinely informative.

Levothyroxine (T4) is often a good option — fewer complications, though it takes longer to dose. But some people, because they’re inflamed, don’t convert T4 well and have a hard time with it. Age and circumstance matter: for a younger woman planning pregnancy, T4 is a strong choice; a middle-aged woman may need support with T3 conversion; in an older woman it depends on her numbers, how she’s doing, and her history.

What guidelines say: levothyroxine monotherapy remains standard first-line treatment. On combination T4/T3 therapy, EMAS states plainly that there are insufficient data in menopausal women to make a recommendation — which isn’t the same as evidence against it, but does mean this is an area of genuine uncertainty rather than established practice.

Our fuller discussion is in Thyroid medication explained: T4, T3 and desiccated thyroid.

Two things that quietly distort thyroid results

Both come up constantly. Almost nobody is warned about either.

Biotin. Biotin is the standard hair, skin and nail supplement — which means it’s being taken by exactly the women who arrive worried about midlife hair thinning. Biotin can produce false TSH, Free T3, Free T4 and Total T4 results on the immunoassays most labs use. EMAS advises having thyroid testing only 2–3 days after stopping a biotin-containing supplement. We tell patients this routinely. If you take a hair supplement and nobody asked, your panel may not mean what it appears to.

Oral estrogen. Oral estradiol raises thyroxine-binding globulin, which can shift TSH and increase the levothyroxine dose a woman needs. Transdermal estradiol doesn’t appear to have the same effect. This is something we see and counsel patients about. If you start oral hormone therapy while on thyroid medication, your thyroid dose may need revisiting — that’s a predictable interaction, not a failure of either treatment.

What hormone testing can and can’t tell you in perimenopause

Hormone testing helps — but not in the way most women hope.

The hard part is that the target keeps moving. In perimenopause you transition a little more, and a little more. Cycle irregularity and hormone fluctuation make a single value genuinely difficult to interpret. One panel is a snapshot of something in motion.

That’s why this stage often means re-checking over time — commonly around every six months, adjusting as things shift, or sooner if someone isn’t feeling well. Some women fluctuate a great deal and need real support through that stretch. We use labs as part of the whole picture rather than treating one hormone snapshot as definitive. Once a woman is fully through menopause, things tend to settle and dosing becomes far more stable.

On timing — and this is worth getting right:

• Luteal-phase assessment, including progesterone, is timed to the luteal phase — often around days 18 to 21 in a typical cycle, adjusted to your actual cycle length rather than a fixed calendar date. This is the timing we commonly use where a cycle still allows it.
• FSH and estradiol, when they’re cycle-timed, are more conventionally assessed in the early follicular phase — not in that days 18–21 window.
• In perimenopause, cycles often stop cooperating with any of this. That difficulty is itself information.

What we’re watching for over time is hormones dropping while FSH and LH rise. That pattern points toward perimenopause.

What guidelines say: perimenopause is generally a clinical diagnosis — age, cycle pattern, symptoms and history — rather than a lab diagnosis, precisely because levels fluctuate. No single hormone value confirms or excludes it. See Perimenopause symptoms, evaluation and testing.

What else can look like both

A thorough sweep matters, because several common things mimic or compound both:

• Blood sugar and insulin — foundational, always looked at.
• Iron — a full iron panel, not just a hemoglobin.
• Vitamin D, B12 and folate.
• Inflammation markers.
• Infections, when clinically indicated.
• Sleep — you can’t be healthy without good sleep.
• Stress, and the rest of diet and lifestyle.

This is where a functional approach earns its keep: looking at the whole lifestyle and all the body systems together, we often uncover patterns that minimal labs would never have surfaced.

What to do if you’re not sure

A practical order when you don’t know which one you’re dealing with:

1. Don’t accept “it’s just your age” as the end of the conversation — or “your thyroid is normal,” if normal meant a TSH by itself.
2. Write down your cycle history, including the direction of change. Longer and heavier, or shorter and skipping?
3. Stop biotin 2–3 days before thyroid labs, and tell whoever orders them what supplements you take.
4. Ask about a fuller thyroid panel including antibodies, not a TSH alone.
5. Ask how sex-hormone testing will be timed to your cycle, where your cycle still allows it.
6. Ask for the foundational work-up too — blood sugar, iron panel, vitamin D, B12, folate, inflammation markers.
7. If thyroid dysfunction is found, treat it and then re-check the hormone picture before drawing conclusions about where you are in the transition.

When to get medical attention sooner

Some things need assessment on their own timeline, separately from all of this: very heavy bleeding or flooding, bleeding between periods, bleeding after intercourse, any bleeding after menopause, a neck lump or swelling, or symptoms that are severe or escalating quickly.

About how this stage gets talked about

We’ll be candid: we don’t think women are supported well through perimenopause and menopause.

The usual framing is that you’ll gain weight, feel unwell, experience vaginal dryness, and decline. It is a change, and the body does change. But properly supported, this can be a time to thrive rather than a time to endure. Women should not simply be told that progressive decline is an unavoidable part of this.

Part of why we take the transition seriously: estrogen receptors are present throughout the body, and the menopause transition can affect tissues and systems well beyond hot flashes — including bone, muscle, skin, genitourinary health, sleep, mood and cognitive symptoms like brain fog.

Worth being precise about that last one. Brain fog and mood changes are real, common features of the transition, and they’re worth addressing. That is a different claim from saying hormone therapy prevents long-term cognitive decline or dementia — it doesn’t establish that, and we’re not claiming it. Symptom effects and proven long-term neuroprotection are two separate questions, and only the first is settled.

Our philosophy on hormone replacement is more proactive than what many women encounter. Women are often taught to view hormone replacement as an optional treatment reserved for severe symptoms. We disagree with that framing. For an appropriately evaluated woman without contraindications, we think it deserves to be considered proactively as part of maintaining quality of life and healthy aging through the transition — with attention to symptoms and quality of life, bone health, muscle, genitourinary and sexual health, sleep, cognition and overall vitality.

And it is genuinely individualized. We are not saying every woman must use hormones. Whether hormone therapy is appropriate — and if so, which route, dose and formulation, and what monitoring goes with it — depends on your personal history, your family history, any contraindications, your risk profile and your goals. Hormone therapy has real contraindications, and that’s exactly why the decision follows a thorough evaluation rather than preceding one. Formal guidelines do not recommend hormone therapy for every woman, and we’re not suggesting they should.

What we are saying is that far too many women are never offered a real conversation about it at all. That conversation belongs to you and your clinician, with your full history in front of you.

The thing we most want you to take away

Patients are often right. When a woman says something is off and a single test says otherwise, the useful move is to keep looking — not to close the question. We don’t like to tell someone it isn’t something until we’ve actually looked properly.

Perimenopause is a natural transition. It’s also a genuinely good moment to look at the whole picture, see where things land, and get things in order so you move into the next part of your life feeling good and energized.

Both can be true — the transition is normal, and something treatable may be sitting alongside it.